NEUROSENSE THERAPEUTICS LTD (NRSN)

IL0011809592 - Common Stock

1.36  +0.08 (+6.25%)

After market: 1.3799 +0.02 (+1.46%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2019 2020 2021 2022 2023 2024 2025 2026
Revenue
YoY % growth
N/AN/AN/A
EBITDA
YoY % growth
-1.24M-2.89M
-133.06%		-5.59M
-93.43%		-13.46M
-140.79%		-11.952M
11.20%		N/AN/AN/A
EBIT
YoY % growth
-1.24M-2.89M
-133.06%		-5.59M
-93.43%		-13.55M
-142.40%		-12.049M
11.08%		N/A
0.55%		N/A
-11.38%		N/A
23.21%
Operating Margin
N/AN/AN/AN/AN/AN/AN/AN/A
EPS
YoY % growth
N/AN/AN/AN/AN/AN/A
14.71%		N/A
23.45%		N/A
32.43%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q3 / 24 Q4 / 24
EPS
Q2Q % growth		-0.16
-263.20%		-0.12
23.50%
Revenue
Q2Q % growth
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		-2.944M
-1.63%		-2.782M
-36.75%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q2 2024
Q2Q % growth		 -0.02
95.45%		-0.200.1890.20%
Q1 2024
Q2Q % growth		 -0.35 -0.21-0.14-67.38%
Q4 2023
Q2Q % growth		 -0.16 -0.200.0421.57%
Q3 2023
Q2Q % growth		 0.10 -0.250.35140.02%
Q2 2023
Q2Q % growth		 -0.44
-41.94%		-0.29-0.15-54.06%
Q1 2022
Q2Q % growth		 -0.24 -0.18-0.06-30.72%
Q3 2021
Q2Q % growth		 -0.24 -0.21-0.03-12.04%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 8.57% 0% 19.44%
RevenueN/A N/A N/A N/A